It is becoming evident that the effects of FGF2 on tumor lymphangiogenesis and progression are far more important than previously assumed.[13, 35] Generally, FGF2 positively correlates with regional LN metastasis in multiple human malignancies, including CSCC.[14] FGF2 plays a role in the lymphangiogenic switch by triggering the activation of lymphatic endothelial cells in cooperation with VEGFs through FGFR1/VEGFR3‐dependent pathways,[26] necessary to disrupt the endothelial lymphatic barrier and facilitate lymphatic invasion. The gene discussed is FGF2; the disease is neoplasm.